Nutshell Therapeutics

Executive Summary

Nutshell Therapeutics is a Shanghai-based preclinical biotech company founded in 2018, specializing in novel small molecule drugs for oncology and immunology. Leveraging structure-based drug design and computational chemistry, the company targets challenging pathways with high unmet medical needs, aiming to develop best-in-class therapies. Despite being early-stage with limited public data, Nutshell's focus on computationally driven discovery and difficult targets positions it within a competitive but potentially high-reward niche in the Chinese biotech landscape. The company has not disclosed funding amounts, but its private status and small team suggest it is likely seeking or in the process of raising capital to advance its pipeline toward IND-enabling studies.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate nomination for oncology program40% success
• Q4 2026Series A financing round closure50% success
• TBDResearch collaboration or licensing deal with major pharma30% success